FDA Guides Drugmakers on Bullseye Rash Lyme Fixes
Published Date: 6/26/2025
Notice
Summary
The FDA just released final advice to help drug makers create treatments for early Lyme disease, especially when it shows up as a bullseye rash called erythema migrans. This update affects companies working on Lyme disease drugs and aims to speed up safe, effective treatments hitting the market. No big cost changes yet, but faster drug development means better care for patients sooner!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA final guidance for Lyme drugs
The FDA released a final guidance titled "Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment" to help drug sponsors with the clinical development of treatments for early Lyme disease shown by an erythema migrans (EM) rash. This final guidance formalizes the draft guidance that was issued on February 1, 2023.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-11808, Elimination of Green and Energy Efficient Mortgage Insurance Premium Rate Category Applicable to Section 232 Mortgages
Starting now, healthcare facilities with FHA-insured loans won’t get special lower mortgage insurance rates for being green or energy-efficient. Instead, all these loans will follow the regular rate set before. This change affects anyone with Section 232 healthcare mortgages and means no extra savings for green upgrades.
Next: 2025-11810, South Atlantic Fishery Management Council (Council); Public Meetings
The South Atlantic Fishery Management Council is hosting a meeting from July 15-17, 2025, to talk about protecting ocean habitats and ecosystems. Fishermen, environmental groups, and coastal communities will get updates and can share their ideas. This meeting helps shape smart rules to keep fish and habitats healthy, with no immediate costs but big benefits for the future.